Dermira Inc.

Plus: Alentis hires Velji as CBO and updates from Empress, Ribbon, Octave, Camena, OM and Transgene

Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen

CHMP’s September opinions also include approval of seven new medicines and label extensions for 11

Backed with $145M since 2020, the biotech has a Phase IIa molecule for atopic dermatitis, plus at least two preclinical programs

Backed with $142M, start-up aims to thread a PK needle for antibody-based radiotherapies, avoiding kidney and bone marrow issues

Plus: Setback for Myovant at FDA and updates from Takeda, Ocugen, Prilenia, AbbVie and more

Plus Huang resigns as BeiGene CMO, Rhee joins GI Innovation as chairman, co-CEO and more

Plus: updates from Karyopharm, Ambys, Lilly, Alexion, Gilead, Exuma, DBV, Armgo, Novartis, Intra-Cellular and A-Alpha Bio and Kymera

Plus: Venture rounds for Lexeo, Evommune, Alamar, and setbacks for Humanigen, Sanofi and more

Plus: $772M IPO for Sino Biological, COVID boosters, Sesen woes, Rigel, Tyvyt, lebrikizumab and more